High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program

• Status: Recruiting
• Trial end date: 2024-12-31
• Target enrollment: 0
• Participant gender: All

Summary

High Risk Population of Cardiovascular Disease in Hubei Province (Coronary Heart Disease With Diabetes) Screening and Intervention Program（CCDInT）is a randomized controlled study to verify that protocol treatment group is more effective than the conventional treatment group in reducing the incidence of composite cardiovascular disease (cardiovascular death, non fatal myocardial infarction, non fatal stroke, hospitalization for heart failure, and readmission for acute coronary syndrome) in patients with coronary heart disease and type 2 diabetes.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wuhan Union Hospital, China
• Collaborator: Peking University First Hospital
• Treatments: Angiotensin-Converting Enzyme Inhibitors; Enzyme Inhibitors; Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

1. 40-75 years old, male or female

2. Patients with coronary heart disease complicated with type 2 diabetes (confirmed by angiography)

3. Low density lipoprotein cholesterol >1.8mmol/l

4. Willing to participate and sign informed consent

Exclusion Criteria:

1. Received coronary stent treatment in recent one year

2. Pregnant or lactating women

3. Decompensated stage of chronic systolic heart failure (NYHA cardiac function rating ≥ 3), cardiac function; Patients with severe cardiovascular complications such as septic shock

4. Stroke patients in recent 1 year

5. Patients with severe gastrointestinal diseases, liver failure or kidney failure

6. Cancer patients or patients who have received radiotherapy or chemotherapy within five years

7. Suffering from infectious diseases such as AIDS and tuberculosis

8. Hospitalized or suffering from other serious diseases requiring immediate hospitalization

9. Bad addicts: drug users or alcoholics (men >80 g / day, women >40 g / day)

10. Disturbance of consciousness, inability to communicate normally or any mental illness; Those who are inconvenient to take care of themselves or move

11. Life expectancy <12 months

12. Individuals with abnormal laboratory tests and clinical manifestations who are judged by the researcher to be unsuitable for participation

13. Unwilling to participate in the trial, unwilling to change the current drug treatment plan